Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: A review

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3722-3730

  Huisman, C ^a   Smit, E F ^a   Giaccone, G ^a   Postmus, P E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METRONIDAZOLE; MITOMYCIN B; NAVELBINE; TOPOTECAN;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0034329630     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3722     Document Type: Review

References (85)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
2. Polychemotherapy in advanced non small cell lung cancer: A meta-analysis
3. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
4. An update on European randomized studies in non-small cell lung cancer
5. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
6. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
7. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
8. Single agents in the second-line treatment of non-small cell lung cancer
9. Management strategies for recurrent non-small cell lung cancer
10. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
11. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial
12. Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
13. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
14. 2 in platinum-pretreated advanced non-small cell lung cancer
15. Phase II study of docetaxel in first- and second-line NSCLC
16. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
17. Phase II trials of Taxotere in patients with non-small cell lung cancer
18. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: Report of a phase II trial
19. Paclitaxel (Taxol®) as a single agent salvage therapy in nonsmall cell lung cancer (NSCLC)
20. Taxol is active as a 3-hour or 24-hour infusion in non-small cell lung cancer
21. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
22. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum-containing chemotherapy
23. Second-line chemotherapy for resistant, metastatic non-small cell lung cancer: The role of Taxol
24. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: Results of an Argentinean multicentre phase II trial
25. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial
26. Second line gemcitabine (GEM) therapy in non-small-cell lung cancer (NSCLC) stage IIIB and IV
27. Activity of gemcitabine (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 trial
28. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC)
29. Gemcitabine as rescue treatment of advanced non-small cell lung cancer: Effect on brain metastasis
30. Improvement of disease-related symptoms with second-line of gemcitabine in advanced non-small cell lung cancer
31. Gemcitabine (GEM) in platinum (PLAT) treated non-small cell lung cancer (NSCLC)
32. Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel
33. Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer
34. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer
35. Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients
36. Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma
37. Vindesine: An effective agent in the treatment of non-small cell lung cancer
38. Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung
39. Clinical development of irinotecan in lung cancers
40. Alimta as a single agent in the therapy of advanced lung cancer
41. Pegylated liposomal doxorubicin (PEG-LD) as second line treatment of advanced non-small cell lung carcinoma (NSCLC) after platinum based therapy: A randomized phase II trial
42. Chronic oral etoposide in non-small cell lung carcinoma
43. 4'-EPI-doxorubicin in advanced lung cancer: A phase II trial
44. Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: A pilot study
45. A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy
46. Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin
47. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer
48. Combination gemcitabine and vinorelbine in the second-line treatment of non-small cell lung cancer (NSCLC): A phase II study of the Minnie Pearl Cancer Research Network
49. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer
50. A phase III study of gemcitabine and vinorelbine salvage chemotherapy for taxane resistant non-small cell lung cancer (NSCLC)
51. Second line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC): A multicenter phase II trial
52. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy
53. A phase I-II trial of topotecan (TOP) and gemcitabine (GEM) for patients with previously treated, advanced non-small cell lung cancer (NSCLC)
54. Mitomycin C, vindesine and cisplatin (MVP) combination as a salvage chemotherapy in pretreated non-small cell lung cancer (NSCLC) patients (pts)
55. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study
56. Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer
57. Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer
58. Carboplatin and paclitaxel for advanced non-small cell lung cancer in previously treated patients
59. Phase I study of irinotecan and cisplatin combination in metastatic non-small cell lung cancer
60. Effective salvage chemotherapy for relapsed or refractory non-small cell lung cancer with mitomycin C, paclitaxel and metronidazole
61. 2) plus vindesine is not an effective salvage regimen for advanced non-small cell lung cancer priorly treated with a cisplatin containing regimen
62. MIC (mitomycin C, ifosfamide, cisplatin) as a secondline treatment for non small cell lung carcinomas
63. Mitomycine, ifosfamide, cisplatin (MIC) as second line regimen in advanced non small cell lung cancer
64. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer
65. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
66. Trial of vindesine plus mitomycin in stage 3 non-small cell lung cancer
67. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer
68. Docetaxel (D) for platinum-refractory non-small cell lung cancer (NSCLC): Comparison of phase II results to historical controls (HC)
69. Docetaxel (D) benefits lung cancer symptoms and quality of life (QoL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-based therapy
70. Chemotherapy resistance in small cell lung cancer: Consequences for the clinician and future prospects
71. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
72. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
73. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials
74. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
75. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
76. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy
77. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer
78. Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian cell lines
79. Preclinical evaluation of docetaxel (Taxotere)
80. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
81. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1,052 patients
82. Prognostic factors in inoperable adenocarcinoma of the lung: A multivariate regression analysis of 259 patients
83. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy
84. E1594-A randomized phase III trial in metastatic non-small cell lung cancer (NSCLC) - Outcome of PS 2 patients (pts): An Eastern Cooperative Group trial (ECOG)
85. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group randomized study